CENTOGENE

Inclusion of 602 patients from 47 countries represents the world’s largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohortStudy identified 287 unique Pathogenic/Likely…

<!-- Name:DistributionId Value:8805367 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8753420 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8744102 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and…

Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR…

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to…

In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential…

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to…

FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and…